AngioDynamics (NASDAQ:ANGO) Issues Earnings Results, Beats Estimates By $0.04 EPS

AngioDynamics (NASDAQ:ANGO) issued its quarterly earnings data on Thursday. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04, Briefing.com reports. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The company had revenue of $67.50 million during the quarter, compared to analyst estimates of $67.93 million. During the same period in the prior year, the business posted ($0.12) earnings per share. The firm’s revenue for the quarter was down 14.2% compared to the same quarter last year. AngioDynamics updated its FY25 guidance to ($0.42)-($0.38) EPS and its FY 2025 guidance to -0.420–0.380 EPS.

AngioDynamics Trading Down 4.2 %

ANGO stock opened at $6.10 on Friday. The business’s fifty day moving average price is $7.48 and its 200 day moving average price is $6.62. AngioDynamics has a 12-month low of $5.26 and a 12-month high of $8.25. The company has a market capitalization of $244.34 million, a PE ratio of -1.26 and a beta of 0.65.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ANGO shares. Canaccord Genuity Group lowered their price target on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research note on Friday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $12.00.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.